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Depression is a highly heterogeneous disease characterized by symptoms spanning
from anhedonia and behavioral despair to social withdrawal and learning deficit.
Such diversity of behavioral phenotypes suggests that discrete neural circuits may
underlie precise aspects of the disease, rendering its treatment an unmet challenge
for modern neuroscience. Evidence from humans and animal models indicate that the
lateral habenula (LHb), an epithalamic center devoted to processing aversive stimuli,
is aberrantly affected during depression. This raises the hypothesis that rescuing
maladaptations within this nucleus may be a potential way to, at least partially,
treat aspects of mood disorders. In this review article, we will discuss pre-clinical
and clinical evidence highlighting the role of LHb and its cellular adaptations in
depression. We will then describe interventional approaches aiming to rescue LHb
dysfunction and ultimately ameliorate depressive symptoms. Altogether, we aim to
merge the mechanistic-, circuit-, and behavioral-level knowledge obtained about LHb
maladaptations in depression to build a general framework that might prove valuable for
potential therapeutic interventions.
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INTRODUCTION
Depression is a mental condition with a long-standing history. Already during the ancient Greek
period, Hippocrates described “Melancholia” as a condition associated with “aversion to food,
despondency, sleeplessness, irritability, restlessness.” Nowadays, the Diagnostic and Statistical
manual of Mental disorders (DSM) defines major depression as a condition with persistent,
unreactive low mood and a loss of interest in pleasure (Telles-Correia et al., 2018). Such symptoms
often occur in parallel with significant weight loss, sleep and psychomotor disturbances, fatigue
and, in certain cases, recurrent thoughts of death or suicide. Despite the large prevalence of this
disorder in our society, the pharmacological tools available are only moderately efficient. Indeed,
approximately a third of treated patients report remission after the first attempt of antidepressant
treatment (Howland, 2008; Dandekar et al., 2018). In this review, we will discuss the available
therapeutic interventions, their limitations, and finally the newest avenues suggested by recent
pre-clinical findings.
Frontiers in Neuroscience | www.frontiersin.org 1 July 2018 | Volume 12 | Article 485
fnins-12-00485 July 19, 2018 Time: 16:32 # 2
Nuno-Perez et al. Lateral Habenula in Depression
SERENDIPITY OR GOAL-DIRECTED
STUDIES: DEPRESSION TREATMENT
Drugs to treat depression were discovered serendipitously in the
1950s with the findings that the antitubercular agent iproniazid
[a monoamine oxidase inhibitor (MAOI)] and imipramine
[tricyclic antidepressant (TCA)] arising from antihistamine
research, partly ameliorated depressive symptoms (Loomer
et al., 1957; Kuhn, 1958). Mechanistically, MAOI inhibits
the breakdown of serotonin (5HT), noradrenaline (NA), and
dopamine (DA) thereby increasing the bioavailability of such
neuromodulators. On the other hand, TCAs increase the synaptic
concentration of 5HT and NA by inhibiting their reuptake.
These findings led to the postulation of a monoaminergic
theory of depression, and to the proposal that 5HT, NA, and
DA neurotransmission are neurobiological substrates for the
pathophysiology of this disorder (Bunney and Davis, 1965;
Schildkraut, 1965; Hirschfeld, 2000). This theory was the basis
of the development of new classes of antidepressants aiming
to normalize monoaminergic deficits. Among these molecules,
the selective 5HT-, NA-, and/or DA-reuptake inhibitors such as
citalopram or fluoxetine are, still nowadays, among the most
prescribed antidepressants (O’Leary et al., 2015). These modern
molecules present less deleterious secondary responses than their
first-generation counterparts (i.e., MAOI and TCAs), yet they
still show slow onset of their clinical effect and, importantly, low
efficacy in many patients (Figure 1) (Baghai et al., 2011).
Given the limited success of such drugs to treat depression,
alternative strategies have been explored and often prescribed
to patients resistant to pharmacological interventions.
Electroconvulsive therapy (ECT) promoted remission from
depressive symptoms in about 75% of pharmaco-resistant
individuals with the advantage of having immediate effects
(Sienaert, 2011). Deep brain stimulation (DBS) of the prefrontal
cortex (Mayberg et al., 2005), nucleus accumbens (Schlaepfer
et al., 2014) or more recently the lateral habenula (LHb; Sartorius
et al., 2010) also ameliorated the symptomatology of drug-
resistant depressed patients. However, despite their promising
therapeutic value, these studies remain preliminary with their
mechanisms of action being still enigmatic.
Altogether, this heightens the need for a more rational
way forward, to clarify the pathophysiology of depression
and ultimately refine therapeutic interventions. This especially
requires a better knowledge of the cellular adaptations within
discrete neuronal circuits during the emergence and progression
of depressive symptoms.
OUT-OF-SYNC HABENULAR ACTIVITY
IN DEPRESSION
A series of human studies raised awareness about the
contribution of the LHb – a brain center regulating motivational
states and aversive encoding – in mood disorders, opening
new possibilities for therapeutic interventions. Volumetric
analysis in humans revealed an interaction between LHb
alterations, gender and the severity of depressive symptoms
(Savitz et al., 2011; Carceller-Sindreu et al., 2015; Lawson et al.,
2017). Furthermore, positron emission tomography unveiled
altered metabolic activity of the habenular complex in patients
experiencing transient depression upon tryptophan depletion
(Morris et al., 1999). Functional imaging data indicated that,
compared to healthy individuals, depressed patients are less
accurate in their expectations regarding objective outcomes,
a phenomenon that occurs with concomitant adaptations in
habenular activity (Furman and Gotlib, 2016). Intriguingly,
individuals with major depressive disorders present abnormal
habenular activation during the presentation of aversive stimuli
and their predictors (Lawson et al., 2017). Finally, a seminal
single case study reported successful remission from pharmaco-
resistant depression after targeting the LHb with local delivery of
high frequency stimulation (Sartorius et al., 2010). Altogether,
these clinical results point to the general idea that dysfunction of
the LHb can be instrumental in the depressive state.
Consistent with such clinical evidence indicating LHb
dysfunction in depression, pre-clinical studies also described
increased metabolic activity in rodent models of depression
(Caldecott-Hazard et al., 1988; Shumake et al., 2003). In
addition, enhanced LHb firing activity was reported in congenital
learned helplessness (LH) rats, a selective breed of animals
displaying depressive-like behaviors (Li et al., 2011, 2013). The
use of alternative animal models recapitulating stress-driven
depressive-like phenotypes, including maternal separation,
inescapable footshock and restraint stress, reproduced a similar
increase of LHb neuronal firing (Lecca et al., 2016; Tchenio
et al., 2017; Authement et al., 2018; Seo et al., 2018; Yang
et al., 2018). This drew a general picture in which insults of
different nature not only commonly contribute to the emergence
of depressive-like states, but also concomitantly lead to LHb
over-activity.
One aspect that remains elusive is whether such stressors
instigate hyperactivity of distinct neuronal populations within the
LHb, potentially representing an ensemble-specific susceptibility.
The use of state-of-the-art technologies such as mini-scopes, to
measure activity of large neuronal ensembles, may provide a
tool to identify groups of neurons engaged by different stressors
for the induction and maintenance of the depressive state. Such
information is relevant especially from a circuit standpoint.
Indeed, LHb neurons send their axons to structures including
the ventral tegmental area (VTA), the rostromedial tegmental
nucleus and the dorsal raphe nucleus (dRN) (Herkenham
and Nauta, 1977), all contributing to motivational states and
depressive symptoms. While some studies infer that depression-
driven LHb neuronal over-activity occurs virtually throughout
the LHb (Li et al., 2013; Lecca et al., 2016; Tchenio et al., 2017),
others suggest instead a certain output specificity (Li et al., 2011;
Meye et al., 2015). Future studies will require to understand the
repercussions that habenular over-activity has on downstream
neuronal populations, and specifically on monoaminergic cells
such as DA and 5HT neurons (Stamatakis and Stuber, 2012).
Lateral habenula neurons fire action potentials with tonic,
irregular, or bursty patterns (Lecca et al., 2017; Yang et al., 2018).
Recent evidence reported that increased bursting activity in LHb
neurons in vivo is instrumental for depression. Notably, restoring
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FIGURE 1 | The available pharmacological treatments for depression mainly employ molecules that target monoaminergic signaling including the 5HT, NA, and DA
system. Such agents broadly act within the brain modulating the tone of neuromodulators in the synaptic cleft. As such this represents a major pitfall of this
treatment, the non-specific control of neuromodulatory systems throughout the brain, which may be at the origin of the low success rate, and secondary effects of
such interventions. The right hand panel summarizes the targets recently highlighted by pre-clinical research on the LHb. DBS, DREADD approaches and K+
channels overexpression reduced neuronal excitability, while other agents are capable to normalize LHb neuronal firing via targeting the PP2A-GABAB-GIRK
signaling, T-type VSCC, NMDARs, or astrocyte function.
such abnormal firing pattern using genetic and pharmacological
approaches ameliorated depressive-like symptoms (Cui et al.,
2018; Seo et al., 2018). Additional studies reported that tonic
firing also increased in animal models of depression, and not
solely bursting (Li et al., 2011, 2013; Lecca et al., 2016; Tchenio
et al., 2017; Seo et al., 2018). One reason that may explain this
discrepancy is that the latter recordings were often obtained in
acute brain slices, which may affect the tonic to burst-firing ratio
in LHb neurons. An obvious solution to this caveat is to monitor
LHb neuronal activity over time by performing multiunit in vivo
electrophysiology in behaving animals (Yang et al., 2018). This
will allow to assess how the biophysical properties of LHb
neuronal populations change during depressive states, although
its achievement is not trivial.
A parallel consideration that deserves attention regards the
behavioral analyses so far employed to define depressive-like
symptoms. Much of the work that has been acknowledged
throughout this review quantified behaviors including despair
or anhedonia, using tests such as the porsolt forced swim test,
the tail suspension test, the shuttle box test or the sucrose
preference test (Tchenio et al., 2017; Seo et al., 2018). Depression
is characterized by a multitude of symptoms, and it is possible
that distinct neuronal circuits control very precise behavioral
traits. Therefore, the possibility of having missed important
information when employing such “classical” behavioral readouts
is omnipresent. To circumvent this issue, the field may take
advantage of computational analysis aiming at decomposing
complex behaviors into simple configurations (Wiltschko et al.,
2015). This strategy may turn out to be valuable in assigning a
given circuit dysfunction, or even a specific cellular adaptation,
to a discrete behavioral pattern. In parallel, developing behaviors
with increased face-validity for the human condition is as well
an important challenge. Recent efforts are providing a new
generation of behavioral tasks with translational potential and
validity across species thereby opening new avenues for a better
assessment of human traits when using animal studies (Der-
Avakian et al., 2016).
NEW TARGETS AND APPROACHES
SUITABLE FOR DEPRESSION
THERAPEUTICS
Identified inputs into the LHb such as the entopeduncular
nucleus of the basal ganglia, the VTA, the hypothalamic nuclei,
and the ventral pallidum are instrumental for aversive behaviors
indicating the sufficiency of habenular circuits for negative
motivational states (Shabel et al., 2012; Root et al., 2014;
Stamatakis et al., 2016; Knowland et al., 2017; Lecca et al.,
2017). In parallel, a series of articles demonstrated that some
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of these synaptic inputs undergo modifications leading to LHb
hyperactivity and ultimately trigger depressive symptoms (Shabel
et al., 2014; Meye et al., 2016; Knowland et al., 2017). Can such
pre-clinical results be at the basis of groundbreaking innovations
for antidepressant treatments?
Pharmacological interventions and currently emerging
alternative strategies present advantages and disadvantages. To
be appropriately designed, both require a profound knowledge
of the molecular mechanisms governing the interplay between
defined circuits. Pharmacology has been proven efficient in
many instances, but is often accompanied by a plethora of
secondary effects and inter-individual variability in terms of
efficacy. On the other hand, strategies such as DBS have been
exploited to restore neuronal defects at the circuit level. Indeed,
DBS stimulation protocols aiming to restore baseline synaptic
transmission between interconnected brain regions were efficient
in normalizing behavioral adaptations in pathological contexts
(Lüscher et al., 2015). In the following paragraphs, we will
summarize the latest advances in restoring LHb neuronal
function and present new ideas for potential therapeutic
interventions in depression.
LHb-Targeted Deep Brain Stimulation
Deep brain stimulation as well as transcranial magnetic
stimulation (TMS) are currently largely exploited FDA-approved
interventions to modulate brain circuitries in pharmaco-resistant
depressed patients. Contrary to TMS, efficient in modulating the
activity of surface brain structures such as the cortex (Diana
et al., 2017), DBS is based on the local implantation of electrodes
in deep brain areas through which high-frequency electrical
currents are applied (Dandekar et al., 2018). This allows to
challenge the function of presynaptic terminals as well as somata,
with the drawback of being non-specific at the cellular and wiring
level.
A seminal work in humans employed DBS in the LHb of a
patient with pharmaco-resistant depression in order to reduce the
neuronal hyperactivity within this nucleus (Sartorius et al., 2010).
Indeed, DBS of the LHb could alleviate depressive symptoms,
with interruption of the stimulation rapidly leading to the
recurrence of depressive periods. This became a breakthrough
in the field, highlighting the relevant contribution of the LHb
to the human condition. However, the community was left with
no evidence regarding how such stimulation was effective, which
neuronal circuits were targeted and whether or not this would
exert negative effects.
Several studies offered a mechanistic explanation for the
efficiency of LHb-targeted DBS protocols. One used congenital
and acute LH models of depression to describe an increased
AMPAR-mediated excitatory drive onto VTA-projecting LHb
neurons during depression (Li et al., 2011). The mechanism
underlying this effect involved an increased probability of
glutamate release from the axon terminals converging onto
this habenular subpopulation. Importantly, when a DBS
protocol adapted from human application was applied in the
LHb of LH rats, this led to a rapid presynaptic reduction
in glutamate release and ameliorated their depressive-like
symptoms. These seminal data suggested, for the first time, a
potential link between a depressive phenotype and a circuit
maladaptation within the LHb. A subsequent study used a
similar DBS approach to rescue depressive-like phenotypes
emerging after early-life stress (Tchenio et al., 2017). A thorough
physiological analysis demonstrated that LHb-DBS application
reduced presynaptic glutamate release and promoted neuronal
hyperpolarization, thereby diminishing the output firing of
habenular neurons. Finally, DBS can also trigger complex LHb-
specific intracellular processes including phosphorylation of
CaMKIIα/β, and GSK3α/β that could eventually contribute to
the antidepressant actions of this intervention (Kim et al.,
2016). These findings not only corroborated the efficiency of the
DBS approach for ameliorating depressive phenotypes, but also
established the causality between LHb overactivity and depressive
states. It is important to state, however, that the underlying
mechanisms leading to LHb hyperactivity in the LH and the
maternal separation models of depression are different. While
the former occurs along with potentiation of AMPA-R-mediated
transmission, the latter requires a reduction in GABAB-R-
mediated signaling (i.e., two alternatives ways by which neurons
become hyper-excitable). This raises the intriguing possibility
that DBS is not rescuing the molecular phenotype itself, but that
it is rather acting directly on the firing of LHb neurons (Figure 1).
The success of these pre-clinical studies in advancing the
mechanistic knowledge about DBS efficiency in the LHb raised
a number of issues that need to be clarified before this approach
can be fully applied in the clinic. Firstly, the mechanisms
underlying the effects of DBS are not fully understood. Additional
research is necessary to evaluate whether all pre-clinical models of
depression are responsive to DBS treatment. Another aspect is the
inherent hijacking that occurs at the circuit level as a consequence
of the DBS application. DBS-driven silencing of LHb neurons
will likely influence a large neuronal population around the
electrode implant. Do these neurons project to different targets?
How do such LHb neurons influence their activity? A potential
way to circumvent this issue is to employ the latest viral
technology such as retrograde adeno-associated or Cav2-cre
viral vectors enabling researchers to perform projection-specific
mapping. These remain fundamental questions to address, as the
LHb controls monoaminergic centers regulating affection and
motivation.
Bearing in mind the limitations of the DBS approach
for the rescue of depressive symptoms in humans, pre-
clinical studies have tried to find alternative strategies with
potential face validity. Along the lines of DBS stimulation, viral
expression and activation of inhibitory DREADDs solely in LHb
neurons, similarly reduced neuronal activity and ameliorated
the depressive-like symptoms in a mouse model of depression
(Tchenio et al., 2017). An intriguing scenario arising from this
finding is the potential use of DREADD technology in humans,
which would allow clinicians to bypass the invasive nature of
DBS implants. However, two major obstacles challenge this
idea: (i) the development of a gene therapy technology allowing
cell type-specific expression of DREADDs in the human brain,
which is still far from being accomplished, and (ii) the use
of the DREADD ligand clozapine-N-oxide (CNO), which has
been claimed to exert various side effects as it is metabolized
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to clozapine (Jann, 1991; Urban and Roth, 2015). Additionally,
overexpression of GIRK channels is sufficient to prevent stress-
driven adaptations in LHb neurons as well as to ameliorate
depressive-like phenotypes (Lecca et al., 2016). Thus, provided
the efficient development of gene therapy in the forthcoming
future, the overexpression of endogenous channels responsible
for neuronal hyperpolarization (e.g., K+ channels) may represent
a potential strategy to overcome the pharmacological drawbacks
of CNO and the lack of circuit specificity of DBS.
Drugging LHb to Ameliorate Depressive
Symptoms
Antidepressants that currently dominate the market mainly
target monoaminergic neurotransmission. However, such
treatments are only efficient in a third of the patients with
depression (Trivedi et al., 2006), leaving the remaining
individuals vulnerable to safety and tolerability issues (Dandekar
et al., 2018). This defines the demand for mechanistically novel
therapeutic interventions as a research priority. Related to this,
recent work identified several “druggable” targets in the LHb
that may prove useful in order to develop a new generation of
antidepressants (Figure 1).
Recent evidence indicate that mice exposed to acute and
prolonged stressors developed depressive phenotypes via protein
phosphatase 2 (PP2A)-dependent GABAB-R-GIRK complex
internalization, which in turn led to LHb hyperexcitability.
Remarkably, systemic or local inhibition of PP2A activity
rescued GABAB-R-GIRK function, neuronal hyperactivity, and
depressive phenotypes. This represents the first neurobiological
use of a membrane-permeable PP2A inhibitor (LB-100) able
to cross the blood–brain barrier, raising the clinical potential
of this compound. Several arguments, however, should reduce
the enthusiasm around this idea. It is questionable whether
PP2A function would be selective for the LHb, raising the issue
of secondary effects, especially given that the phosphatase is
ubiquitous (Wlodarchak and Xing, 2016). This is relevant since
the PP2A-dependent control of GABAB-R-GIRK signaling occurs
in other brain structures including the VTA and the cortex
(Padgett et al., 2012). A promising indication, however, is that
increased levels of PP2A mostly occur in pathological conditions
(e.g., addiction and depression), thereby supporting the notion
that the use of such inhibitor at a correct dose may not have
major negative consequences. Certainly, more pre-clinical data
are needed to corroborate the potential of this molecule by using
different animal models and studying its effects on different
depressive-like symptoms.
Other targets have also been highlighted. Two recent studies
(Cui et al., 2018; Yang et al., 2018) described increased bursting
activity in LHb neurons of congenital LH rats, a phenotype
requiring NMDA-Rs, low-voltage-sensitive T-type calcium
channels (T-VSCCs) and the upregulation of the astroglial
potassium channel Kir 4.1. These results point to a variety of
channels that might represent viable targets for antidepressants.
For example, antagonizing T-VSCCs via the commercially
available antiepileptic compound ethosuximide could diminish
bursting activity within the LHb, subsequently ameliorating
depressive-like phenotypes. More pre-clinical studies are
necessary to rule out eventual secondary effects, as these channels
are fundamental for the firing properties of numerous neuronal
populations (Nanou and Catterall, 2018).
Another molecule that is attracting a great deal of attention
primarily in the context of mood disorders is ketamine. Defined
as a NMDA-R inhibitor, ketamine represents a rapidly acting
antidepressant proposed for the treatment of major depression,
although its mechanisms of action remain debated and obscure
(Zanos et al., 2016). Yang et al. (2018) found that infusion of
ketamine into the LHb was sufficient to ameliorate depressive-
like symptoms in LH rats. These findings suggest that the
therapeutic actions of ketamine might emerge, at least partly, via
the reduction of firing and especially bursting of LHb neurons.
Whether the negative effects of ketamine (i.e., psychotic state) are
linked to different neuronal circuits or to the LHb remains to be
established.
Finally, Cui et al. (2018) raised the possibility of targeting
astroglial K+ channels as an antidepressant treatment. In this
work, an unbiased proteomic analysis identified the upregulation
of the astrocytic Kir4.1 channel in the LHb of LH rats.
Physiological assessment and viral-based approaches causally
linked the increased levels of Kir4.1 with the LHb neuronal
hyperactivity and the eventual establishment of the depressive
state. Hence, this work highlights that the functional modulation
of glial cells within the LHb may represent an interventional
approach to treat depression. One of the major breakthroughs
of this study is the description that Kir4.1 is solely expressed in
astrocytes, thereby suggesting that its pharmacological targeting
would spare neurons. However, how acting on such channels
throughout the brain will affect K+ homeostasis and thus
neuronal excitability is a crucial point that needs careful
evaluation.
The same proteomic approach revealed that Kir4.1 was not
the only protein overexpressed in depressed rats. Indeed the
neuronal bCamKII levels were shown to be significantly higher
in the LHb of LH rats compared to their control counterparts (Li
et al., 2013). LHb-restricted genetic manipulations of bCamKII,
together with physiological approaches, ultimately indicated that
reducing its levels rescued the LHb overactivity and ameliorated
the depressive symptoms.
Altogether, these data argue that a variety of manipulations
affecting the activity of LHb neurons either directly or indirectly
through astrocytes (Cui et al., 2014, 2018) might be efficacious
in rescuing depressive-like phenotypes. Considerable efforts will
be necessary to clarify the hierarchical sequence of events that
are responsible for aberrant LHb activity in depression. This is
crucial for a field that aims to provide solid, reproducible pre-
clinical data to design modern interventions capable of treating
different aspects of mood disorders, ultimately ameliorating the
human condition.
CONCLUDING REMARKS
The majority of the studies reported here examined tonic
activity of LHb in the context of depression. Yet LHb neurons
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physiologically permit the encoding of aversive stimuli and their
predictors, mediating innate and learned behavioral responses
(Matsumoto and Hikosaka, 2007). It remains however unclear
how the depressive state mechanistically affects such primary
encoding. Evidence exist suggesting that this is the case in
humans, but pre-clinical studies have now the opportunity to
unravel the circuit and cellular underpinning of this process
(Furman and Gotlib, 2016; Lawson et al., 2017).
The clinical studies discussed in this review suggest that
targeting the LHb with DBS supports its therapeutic potential,
however less clear is the efficacy of pharmacological strategies
acting at the level of this nucleus to treat depression. Although
the data presented above are exciting, the sole molecule close
to have a valuable societal impact is ketamine, despite its dark
side. Advancing our knowledge of potential treatments targeting
the LHb requires synergistic action from both fundamental
and clinical neuroscience. This can be obtained, for instance,
by performing double-blind studies on a much larger cohort
of patients to properly evaluate the clinical utility of LHb
targeting in mood disorders. On the pharmacological front,
drugs acting at identified targets within the LHb, and shown
successful in rescuing cellular phenotypes, should be further
evaluated for their efficiency in ameliorating depressive states
in additional animal models and ultimately in humans. Such
research line may overtime increase the armamentarium of
clinically-relevant interventional approaches to treat discrete
aspects of depression.
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